Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'.
'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology."
With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia.
In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction.
With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution.
Related
EU pharma chief calls for European Nasdaq to boost biotech innovation
Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R
'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi.
The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
39 minutes ago
- USA Today
Trump trade deal with EU leaves Europe relieved − and worried
The Europe trade deal will see the U.S. impose a 15% import tariff on most EU goods − half the threatened rate but much more than Europeans hoped for. BRUSSELS − European governments and companies reacted with both relief and concern on Monday to the framework trade deal struck with President Donald Trump, acknowledging what was seen as an unbalanced deal but one that avoided a deeper trade war. The agreement, announced on July 27 between two economies that account for almost a third of global trade, will see the U.S. impose a 15% import tariff on most EU goods − half the threatened rate but much more than what Europeans hoped for. Many of the specifics of the deal were not immediately known, however. More: Trump and EU reach trade deal ahead of looming deadline "As we await full details of the new EU–U.S. trade agreement, one thing is clear: this is a moment of relief but not of celebration," Belgian Prime Minister Bart De Wever wrote on X. "Tariffs will increase in several areas and some key questions remain unresolved." Trump said the deal, including an investment pledge topping the $550 billion deal signed with Japan last week, would expand ties between the trans-Atlantic powers after years of what he called unfair treatment of U.S. exporters. It will bring clarity for European makers of cars, planes and chemicals. But the EU had initially hoped for a zero-for-zero tariff deal. And the 15% baseline tariff, while an improvement on the threatened rate of 30%, compares to an average U.S. import tariff rate of around 2.5% last year before Trump's return to the White House. More: Trump considers 'rebates' to US taxpayers from tariff income European Commission chief Von der Leyen, describing Trump as a tough negotiator, told reporters on July 27 that it was "the best we could get." European stocks opened up on July 28, with the STOXX 600 at a four-month high and all other major bourses also in the green. Tech and healthcare stocks led the way. More: TACO or tariffs? Trump's big trade deadline is coming. Here's what to expect "The 15% rate is better than the market was fearing," said Jefferies economist Mohit Kumar. German Chancellor Friedrich Merz welcomed the deal, saying it averted a trade conflict that would have hit Germany's export-driven economy and its large auto sector hard. Not the end of the story French government ministers said on July 28 that the deal had some merits − such as exemptions they hoped to see for some key French business sectors such as spirits − but was nevertheless not balanced. Industry minister Marc Ferracci stressed more talks - potentially lasting weeks or months - would be needed before the deal could be formally concluded. "This is not the end of the story," he told RTL radio. European companies, meanwhile, were left wondering whether to cheer or lament the accord. "Those who expect a hurricane are grateful for a storm," said Wolfgang Große Entrup, head of the German Chemical Industry Association VCI. "Further escalation has been avoided. Nevertheless, the price is high for both sides. European exports are losing competitiveness. U.S. customers are paying the tariffs," he said. Stellantis shares were up 3.5% and car parts maker Valeo jumped 4.7% while German pharma group Merck KGaA rose 2.9%, in a sign of relief for those sectors. Among the many questions that remain to be answered, however, is how the EU's promise to invest hundreds of billions of dollars in the U.S. and steeply increase energy purchases can be turned into reality. It was not immediately clear if specific pledges of increased investments were made or whether the details still must be hammered out. And while the EU pledged to make $750 billion in strategic purchases over the next three years, including oil, liquefied natural gas (LNG) and nuclear fuel, the U.S. will struggle to produce enough to meet that demand. While U.S. LNG production capacity is due to almost double over the next four years it will still not be enough to ramp up supplies to Europe, and oil production is expected to be lower than previously forecast this year. Despite the lingering unknowns, analysts stressed the deal still helped decrease uncertainty. Oil prices rose on Monday, as did the euro. "Now that there is more clarity, you would think that not only in the United States, but around the globe, there will be a little bit more willingness to look at investment, to look at expansions, and to look at where the opportunities are," said Rodrigo Catril, senior currency strategist at National Australia Bank.
CNBC
5 hours ago
- CNBC
China's Laopu Gold shares fall despite forecast of tripling profits
Shares of Laopu Gold fell to their lowest levels since May 20 after the Chinese jewelry upstart forecasted its net profit for the first half of 2025 would increase between 279% and 288% year over year, or between RMB 2.23 billion and RMB 2.28 billion ($311.11 million to $318.08 million). The stock, which is up 203.07% for the year to date, rose nearly 4% in early trade, but pared back gains as investors locked in their profits. While shares of Laopu Gold are on course for their ninth straight session of decline, they have skyrocketed by more than 2,000% since their listing last year. The Hong Kong-listed company also reported in a filing to the Hong Kong stock exchange on Sunday that its projected revenue for the first half of the year would increase between 241% and 255% from the same period last year. Concerns over rising gold prices and market downgrades in earning expectations have caused the stock to fall from its peak in early July, Morgan Stanley analysts said in a research report on Monday. Citi analysts also attributed the retreat in Laopu's share price to a reset in market expectations and "unwinding fund flow," adding that the stock appears relatively cheap. However, consulting firm Oliver Wyman said that Laopu's earnings are less tied to fluctuations in gold prices, unlike traditional jewelers, due to the designs of its products, which blend ancient craftsmanship with contemporary appeal. The Chinese jewelry brand was founded in 2009 and is popular among younger consumers for its distinctive designs, including ancient coin pendants and lotus motifs. "We believe Laopu's current valuation has become more attractive in the past three weeks despite the company's intact growth story", Nomura analysts said in a report. The Beijing-based company attributed the increase in its top and bottom lines to the brand's expansion online and through offline boutiques. Laopu has boutiques in Shanghai, Shenzhen and Hong Kong, and opened its first overseas store at Singapore's Marina Bay Sands in June. Laopu's success contrasts with more tepid consumer spending in China. Affluent Chinese are more negative on the economy than they were during the pandemic, according to a survey released last week by Oliver Wyman. The report found that many respondents are shifting their spending away from luxury goods toward experiences, such as travel. Similarly, Labubu-maker Pop Mart had issued an upbeat profit forecast for the first half of 2025 earlier this month, but initially dropped on the news. Pop Mart shares are up by 175.74% year-to-date. In contrast, shares of Chinese sportswear company Anta have increased by 17.15% so far this year. The company's said in a filing that it achieved "mid-single digit positive growth" for house brand products and "high-single digit positive growth" for Fila-branded products for the first half of this year.
Yahoo
5 hours ago
- Yahoo
Kepler Capital Maintained a Buy Rating on Genfit (GNFT)
Genfit S.A. (NASDAQ:GNFT) is one of the . On July 8, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit S.A. (NASDAQ:GNFT) with a price target of €8.40. The rating comes after the company released its mid-year update on its liquidity contract with Credit Industriel et Commercial. The company noted that as of June 30, 2025, there were 201,000 shares in the liquidity account along with €398,484.67 in cash in liquidity. Moreover, the company also released details about its trading activity, which shows 1,412,901 shares were bought, 1,419,301 shares were sold, with the number of buy and sell trades standing at 2,673 and 1,894, respectively. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company that develops treatments and diagnostic tools for rare and serious liver diseases. While we acknowledge the potential of GNFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
